Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1406916 | 0.84 | NR4A3 (0.40) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL1407182 | 0.83 | NR4A3 (0.36) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL1406669 | 0.81 | NR4A3 (0.41) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL3294253 | 0.79 | NR4A3 (0.54) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL10365996 | 0.77 | NR4A3 (0.42) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL14413274 | 0.77 | NR4A3 (0.42) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL3291164 | 0.76 | NR4A3 (0.44) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL3293452 | 0.76 | NR4A3 (0.35) | NR4A3LMNA | |
| SCHEMBL3293316 | 0.75 | NR4A3 (0.38) | NR4A3NPC1TP53RAB9AKDM4E | |
| SCHEMBL10368484 | 0.75 | NR4A3 (0.40) | NR4A3NPC1TP53RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1999114-B1 | PYRAZOLES AS 11-BETA-HSD-1 | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2295411-A1 | Pyrazoles as 11-beta-hsd-1 | F. Hoffmann-La Roche AG (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | NR4A3 2221/4885NPC1 856/4885TP53 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.